Immunotherapies
CAR T Cell Therapy is a type of immunotherapy where a patient’s own immune cells (T cells) are modified by adding a special receptor (CAR) to their surface. This gives T cells the ability to better target and help kill cancer cells since the CAR recognizes a marker found on certain cancer cells, as well as on some healthy cells.
CAR T therapy requires several steps that typically occur over 1–2 months but is infused in one day.

Bispecific Antibodies are a therapy that brings together two different cells – one being the unhealthy cell and the other being an immune cell. This allows the immune cell to come in close contact with the unhealthy cell and become activated to fight it.
Bispecific antibodies are typically administered by injection or through an IV and are given until disease progression or unacceptable toxicity.

Antibody-Drug Conjugates (ADCs) combine an antibody, a protein that helps the immune system identify harmful substances, that can attach to specific cells with a cytotoxic drug (similar to chemotherapy). In this way, the ADC can target and kill certain unhealthy cells like cancer.
ADCs are typically administered through an IV and are given until disease progression or unacceptable toxicity.
